Travere Therapeutics, Inc. (TVTX): M&A transaction — Travere closes $210M asset sale to Mirum; eligible for up to $235M in milestones

Travere Therapeutics, Inc.

Upfront cash payment of $210M from Mirum for Chenodal and Cholbam assets.
Potential milestone payments up to $235M based on annual net sales tiers ($125M-$500M).
Transaction closed on August 31, 2023, as previously announced on July 16, 2023.
Pro forma financial statements to be filed by amendment within four business days.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Travere Therapeutics, Inc. completed a disposition involving Mirum Pharmaceuticals, Inc. for $210,000,000 (closed 2023-08-31).

Action: disposition
Counterparty: Mirum Pharmaceuticals, Inc.
Consideration: $210,000,000
Closing: 2023-08-31

Exact text from the filing

of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”). In connection with the Closing, Mirum paid the Company an upfront cash payment of $210,000,000. Pursuant to the Purchase Agreement, after the Closing, the Company is eligible to receive up to $235,000,000 upon the achievement of certain milestones based on specified

View on SEC.gov

32 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-228130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.